Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens
You may also be interested in...
Cipla Backs Chase For Alzheimer’s Drug Research
The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.
Cipla Backs Chase For Alzheimer’s Drug Research
The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.
After Death Of Cipla Former Joint Managing Director Amar Lulla, Will Vision Of Veteran Continue?
MUMBAI - After jointly serving at the helm of Cipla for more than three decades, Joint Managing Director Amar Lulla died April 22 after a prolonged and debilitating battle with cancer. To the world, Cipla Chairman Yusuf Hamied was the face of the company - fighting global pharmaceutical companies to bring down prices of anti-HIV and anti-cancer medications - but to those within the organization, Lulla remained the single driving force, handling the complexities of the generic drugs market in India and working steadily to keep Cipla competitive